Contract HHSO100201700018C
Janssen Pharmaceuticals, Inc. · Department Of Health And Human Services · August 15, 2017
Janssen Pharmaceuticals, Inc. was awarded a federal contract by Department Of Health And Human Services (Office Of Assistant Secretary For Preparedness And Response) on August 15, 2017 for $919.51 million of work in research and development in biotechnology. It was awarded under full and open competition. The contract has been modified 20 times since the base award It uses cost sharing contract pricing. The most recent modification was on April 23, 2025.
Contract details
- PIID
- HHSO100201700018C
- Award type
- —
- Pricing
- Cost Sharing
- Set-aside
- No Set Aside Used.
- Competition
- Full And Open Competition
- NAICS
- 541711 · Research And Development In Biotechnology
- Product / service
- Drugs And Biologicals
- First action
- August 15, 2017
- Latest action
- April 23, 2025
Description
EOI::EO: RADICAL TRANSPARENCY ABOUT WASTEFUL SPENDING::EOI BILATERAL MODIFICATION TO DESCOPE WORK AND DEOBLIGATE FUNDS.
Modification timeline
-
April 23, 2025Mod P00020$-100.00M
-
August 8, 2024Mod P00019JANSSEN INFLUENZA PORTFOLIO AND OTHER EMERGING PATHOGENS DEVELOPMENT CANDIDATES$-241.63M
-
September 20, 2022Mod P00018JANSSEN INFLUENZA PORTFOLIO AND OTHER EMERGING PATHOGENS DEVELOPMENT CANDIDATES$0
-
March 4, 2022Mod P00017THE PURPOSE OF THIS AMENDMENT IS TO UPDATED SOW REFLECTS DISCUSSIONS HELD BY BOTH PARTIES DURING THE IN-PROCESS REVIEW (IPR) ON MAY 4, 2021, AND THE RESULTING E$0
-
January 19, 2022Mod P00016THE PURPOSE OF THIS AMENDMENT IS TO MAKE BILATERAL CHANGES WITHIN THE GENERAL SCOPE OF THIS AGREEMENT TO (I) RELINQUISH USG?S OWNERSHIP INTEREST IN 8,320 VIALS$0
-
June 1, 2021Mod P00015THE PURPOSE OF THIS AMENDMENT IS TO MAKE BILATERAL CHANGES WITHIN THE GENERAL SCOPE OF THIS AGREEMENT TO (I) RELINQUISH USG?S OWNERSHIP INTEREST IN 8,320 VIALS$0
-
March 31, 2021Mod P00014THE PURPOSE OF THIS AMENDMENT MAKES BILATERAL CHANGES WITHIN THE GENERAL SCOPE OF THIS AGREEMENT TO (I) RELINQUISH USG?S OWNERSHIP INTEREST IN 100,000 VIALS OF$0
-
March 15, 2021Mod P00013THE PURPOSE OF THIS AMENDMENT IS TO UPDATE THE SCOPE OF WP 6.17 RELATED TO COVID-19 VACCINE R&D EFFORTS. IN ADDITION, OPTION WPS 6.11 & 6.112 HAVE BEEN ELIMINA$32.00M
-
February 11, 2021Mod P00012THIS AMENDMENT 12 AGREEMENT MAKES BILATERAL CHANGES WITHIN THE GENERAL SCOPE OF THIS AGREEMENT TO (I) RELINQUISH USG'S OWNERSHIP INTEREST IN 150,000 VIALS OF$0
-
November 13, 2020Mod P00011THIS AMENDMENT, BASED ON JOINT OVERSIGHT COMMITTEE (JOC) RECOMMENDATION, DOCUMENTED IN MEMO #12 DATED 16 JUNE 2020, AND IN ACCORDANCE WITH ARTICLE IV OF THE OTA$454.31M
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| University Of Illinois | Department Of Health And Human Services | March 26, 2026 | $2.27M |
| Battelle Memorial Institute | Department Of Health And Human Services | March 25, 2026 | $9.65M |
| University Of Texas Medical Branch At Galveston | Department Of Health And Human Services | March 23, 2026 | $1.61M |
| Regeneron Pharmaceuticals Inc | Department Of Health And Human Services | March 19, 2026 | $8.60M |
| Battelle Memorial Institute | Department Of Health And Human Services | March 17, 2026 | $2.23M |
| Battelle Memorial Institute | Department Of Health And Human Services | March 17, 2026 | $2.22M |
Top contractors in NAICS 541711
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | Alliance For Energy Innovation, Llc | 2 | $10.68B |
| 2 | Emergent Product Development Gaithersburg Inc. | 7 | $1.63B |
| 3 | Janssen Pharmaceuticals, Inc. | 2 | $1.05B |
| 4 | Regeneron Pharmaceuticals Inc | 4 | $1.01B |
| 5 | Siga Technologies, Inc. | 3 | $560.59M |
| 6 | Battelle National Biodefense Institute, Llc | 106 | $469.31M |
| 7 | Glaxosmithkline, Llc | 6 | $321.65M |
| 8 | Merck Sharp & Dohme Llc | 3 | $309.72M |
| 9 | Sri International | 130 | $258.61M |
| 10 | American Type Culture Collection | 7 | $243.18M |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract HHSO100201700018C?
Contract HHSO100201700018C is a federal contract awarded to Janssen Pharmaceuticals, Inc. by Department Of Health And Human Services on August 15, 2017 for $919.51 million of work classified under RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY. It has been modified 20 times since the base award.
Who won contract HHSO100201700018C?
Janssen Pharmaceuticals, Inc. won contract HHSO100201700018C from Department Of Health And Human Services.
How much is contract HHSO100201700018C worth?
Contract HHSO100201700018C has obligated $919.51 million to date.